

IPA 2020 Medicinal Cannabis Conference on:

IMPORT & EXPORT OF MEDICINAL CANNABIS
MAY 6, 2020

MEDICINAL CANNABIS SCIENCE & RESEARCH
MAY 7-8, 2020



About the Conference



International Pharmaceutical Academy (IPA) is delighted to be hosting its 2020 Medicinal Cannabis Conference on May 6-8, 2020 in Toronto, Canada. The three-day Conference will provide attendees with insight and a plethora of information on import and export, research and science of medicinal cannabis.

The first day of the conference will address the current Canadian & International regulation requirements, and permits for the import & export of cannabis for medical and scientific purposes.

We will begin our Medicinal Cannabis Science & Research conference on day two, May 7, 2020. The two-day event will expose attendees with the current updates, innovations and discoveries in the research, science and analytical testing of medicinal cannabis.

The "IPA 2020 Medicinal Cannabis Conference" is the place to be for an unparalleled learning experience and networking opportunities!

We expect some great presentations being delivered, followed by lively discussion during the extensive Q&A and interactive discussion sessions.



Distinguished Speakers - Import & Export of Medicinal Cannabis | May 6, 2020



Alice Gheorghiu

*Manager of Industrial Hemp and Import/Export
Controlled Substances and Cannabis Branch*
Health Canada



Alice Gheorghiu is the manager of the industrial hemp and import/export units within the Controlled Substances and Cannabis Branch at Health Canada since 2019. Her work focuses on establishing and enforcing legal and regulatory frameworks in the field of industrial hemp and cannabis in Canada, overseeing the authorizations necessary to conduct various activities in these fields as well as establishing and maintaining stakeholder relations.

Alice has over ten years of experience in the federal public service and in public administration questions and issues.

Alice has a bi-disciplinary bachelor's degree in political science and communication from the University of Montreal and a master's degree in public and international affairs from York University.



Vincent Sliwoski

Partner
Harris Bricken



Vincent Sliwoski is a partner with Harris Bricken. He runs the firm's Oregon office, and his clients run the gamut from individual investors and entrepreneurs to widely held domestic and international corporations. Since 2011, he has represented a large number of cannabis entities through corporate structuring, commercial transactions, and early stage dispute resolution.



Marion Zammit

Malta's Government economic development agency, responsible for supporting the Medical Cannabis Industry, along with other sectors, Malta Enterprise



Marion Zammit works in the Investment Promotion Department within Malta Enterprise, Malta's economic development corporation.

Marion holds a Bachelors Degree in Biology and Chemistry from the University of Malta, and a Masters Degree in Business Administration from the same University.

Her career has included various positions in the advanced manufacturing sector, including quality, production processing, as well as logistics and supply chain. Marion has worked and gained experience in the Pharmaceutical Sector, both in manufacturing as well as sales and marketing.

At Malta Enterprise, Marion supports various sectors including Medical Cannabis, Pharma, and other projects of national interest. Over the past two years, Marion has been focusing specifically on the Medical Cannabis Sector, working very closely with all the stakeholders, in order to ensure an effective roll-out of the strategy for this new ecosystem in the Maltese Economy.

Marion has established herself as a prominent figure in the International Medical Cannabis arena, having attended various international conferences and medical cannabis events, as well as contributed to articles and interviews in various renowned publications

Distinguished Speakers - Import & Export of Medicinal Cannabis | May 6, 2020



Martha Smit

Partner, Qualified registered nurse and lawyer

Fasken, Johannesburg

FASKEN



Martha Smit is a partner in our Johannesburg office and a member of the firm's Life Sciences practice group.

Qualified as both a registered nurse and lawyer, Martha brings compelling experience in the legal, medical and pharmaceutical industries.

Having practised as a litigation attorney and legal advisor in the corporate sector as well as coordinating clinical data trials for an international pharmaceutical company, she is able to bring the best of both worlds in finding innovative solutions for clients and businesses in the Life Sciences area. She also holds a current Good Clinical Practice Certificate for Clinical Research.

Martha's practical experience of having worked across a number of professional health bodies and corporates has afforded her first-hand knowledge and an in-depth understanding of the challenges, opportunities and regulatory environments of this sector.



Daniel Podestá

Partner,

Estudio Podestá



Daniel is a lawyer with more than fifteen years of experience, he is partner at Estudio Podestá, law firm based in Montevideo, founded in 1978.

Since 2013, he has specialized in regulatory framework for hemp and cannabis industries in Uruguay, advising companies throughout the process of obtaining the various authorizations before public authorities, as well as import/export process, implementing and controlling them for the correct development of the project.

Daniel also assists cannabis companies on corporate needs and M&A.

On October 2018 Daniel was appointed as general secretary of the Chamber of Medicinal Cannabis Companies for the period 2018-2020



Dr. Valentina Vaguengueim, MBA

Senior Manager, Risk Advisory

CCI Deloitte



Valentina, a Senior Manager, Risk Advisory at CCI Deloitte, has over 15 years of Pharmaceutical, Clinical Research, Biotech and Cannabis industries experience in regulated environments of Canada, USA, South America, Asia and Europe. In the course of her career, Valentina worked for pharmaceutical and clinical research giants as well as smaller innovative firms providing strategic leadership of all aspects of operations, regulatory compliance, innovation, client relationships and project management. She was involved in research of innovative technologies and the development and growth of a small business. Valentina holds a PhD in Technical Sciences - Pharmaceutical Technology and Biotechnology and an Executive MBA.

Distinguished Speakers - Import & Export of Medicinal Cannabis | May 6, 2020



Karina Lahnakoski, MBA, B.Sc, PMP
Partner, Risk Advisory
CCI Deloitte



Karina is a Partner in Deloitte's Risk Advisory Practice and oversees CCI Deloitte's regulatory and compliance operations to provide end-to-end business solutions at every stage of the cannabis business cycle including Licensing, Operational Compliance, Auditing, NHP, GMP implementation, Cultivation, Security and Business planning for the cannabis industry.

Karina brings the skillset of navigating challenging regulatory pathways in new markets to the cannabis space. Prior to joining CCI Deloitte Karina was Vice President of Quality and Regulatory at Cannabis Compliance Inc. (CCI) working with the cannabis industry to achieve licensing and improve their operations. Karina comes from a bio/pharmaceutical and medical device background where she held leadership positions with Dalton Pharmaceutical Services, Contract Pharmaceuticals Ltd and Amorfix Life Sciences. Karina has worked on commercialization and regulatory path for over 150 cannabis, pharma and device products in her time.

Karina holds a Master's in Business Administration (MBA) from York University and B.Sc in Biochemistry from University of Guelph. She is also a certified Project Management Professional (PMP).



Deepak Anand, MBA
Chief Executive Officer and Director
Materia



Mr. Anand has a wealth of knowledge and experience in the global cannabis industry. He is a public speaker and is regularly engaged with Canadian and International media on all subjects related to the Cannabis industry. Mr. Anand holds a Master's in Business Administration (MBA) and Management from Vancouver Island University. He is a recognized thought leader and brings 15 years of leadership experience in the health, charitable/non-profit, and private sectors in Canada.

Within the global cannabis sector, Mr. Anand has worked with senior government officials, politicians, policy makers, health professional organizations, clinical practitioners, educators, investor, patients as well as producers. He has also served on the boards of various pharmaceutical associations across Canada, the United States and Europe.

Currently, Mr. Anand serves on a variety of boards within the international cannabis space which include not for profit, advocacy and patient driven organizations

Prominent positions, Mr. Anand has previously held in the Cannabis industry include:

- Vice President of Business Development and Government Relations at Deloitte- CCI., Canada.
- Vice President for Zenabis Global Inc. (A Health Canada License Holder) with operations in Canada and Malta.
- Adjunct Professor at Kwantlen Polytechnic University (KPU). At KPU, Mr. Anand wrote, and taught Canada's first and only Cannabis course titled 'Cannabis Professional Series' taught via an online module.
- Executive Director for the Canadian National Medical Marijuana Association (CNMMA). The CNMMA was the first and only industry association that factored in all facets of the nascent Cannabis industry in Canada.

Preliminary Conference Agenda

Day 1 – Wednesday May 6, 2020 | Import & Export of Medicinal Cannabis

8:00 AM – 8:45 AM Registration, Networking and Continental Breakfast
8:45 AM- 9:00 AM Chair's Welcome Note – Day 1
9:00 AM – 9:45 AM Canadian regulation requirements regarding permits for the import or export of cannabis for medical or scientific purposes • Legislative and regulatory frameworks • Limited circumstances under which imports/exports are authorized • Import/Export Permits issuance process Presented by: Alice Gheorghiu, Manager of Industrial Hemp and Import/Export, Controlled Substances and Cannabis Branch, Health Canada
9:45 AM - 10:45 AM Export of Medical Marijuana to the U.S. and Worldwide • Legal status of medical marijuana under international law • Legal status of medical marijuana import/export under international law • Import permits and requirements • International Narcotics Control Board reporting requirements • Export to the United States Presented by: Vincent Sliwoski, Partner, Harris Bricken
10:45 AM – 11:00 AM Mid-morning Refreshment Break
11:00 AM – 11:45 AM Import & Export of medicinal cannabis on Latin America • Law frameworks (Argentina, Brazil, Chile, Colombia, Uruguay) • Permits and requirements • Public bodies involved • Import/Export for compassionate use Presented by: Daniel Podestá, Partner, Estudio Podestá
11:45 AM – 12:15 PM Panel Q & A, Discussion Alice Gheorghiu, Health Canada Vincent Sliwoski, Harris Bricken Daniel Podestá, Estudio Podestá

Note: Agenda is subject to change without notice. Please check back regularly for updates.

Preliminary Conference Agenda

Day 1 - Continued

12:15 PM – 13:15 PM Lunch
13:15 PM – 14:00 PM Legalisation of Cannabis in South Africa: High on our list of priorities Cannabis in South Africa: Regulatory requirements for import/export Presented by: Martha Smit, Partner, Qualified registered nurse and lawyer, Fasken, Johannesburg
14:00 PM – 14:30 PM Malta – An Ideal Jurisdiction for Medical Cannabis Presented by: Marion Zammit, Malta's Government economic development agency, responsible for supporting the Medical Cannabis Industry, along with other sectors, Malta Enterprise
14:30 PM – 14:45 PM Mid-Afternoon Refreshment Break
14:45 PM – 15:45 PM Import & Export of Medicinal Cannabis in Europe, UK & Australia Presented by: Deepak Anand, MBA, Chief Executive Officer and Director, Materia
15:45 PM - 16:30 PM GMP Certification and Manufacturing in EU • Business cases that require GMP • How long does it take • Where does GMP start Presented by: Karina Lahnakoski, Partner, Risk Advisory, CCI Deloitte, Deloitte LLP Presented by: Valentina Vaguengueim, Senior Manager, Risk Advisory, CCI Deloitte, Deloitte LLP
16:30 PM - 17:00 PM Panel Q & A, Discussion Martha Smit, Fasken, Johannesburg Marion Zammit, Malta Enterprise Deepak Anand, MBA, Materia Karina Lahnakoski, CCI Deloitte, Deloitte LLP Valentina Vaguengueim, CCI Deloitte, Deloitte LLP
17:00 PM Conclusion of Day 1 Conference

Note: Agenda is subject to change without notice. Please check back regularly for updates.



Céline Beaupré

*Manager of Specialized Authorization
Controlled Substances and Cannabis Branch*
Health Canada



Céline Beaupré is the manager of the Special Licences and Exemptions Section within the Controlled Substances and Cannabis Branch at Health Canada, a position she has held since 2018. Céline has a background in agronomy and has over 10 years of experience in the federal public service developing regulatory frameworks and delivering programs. Céline is currently responsible for the licensing framework under the Cannabis Act and Cannabis Regulations to conduct activities in relation to research and analytical testing involving cannabis.



Dr. Richard J. Huntsman, MD, FRCP(C), CSCN(EEG)

**Jim Pattison Children's Hospital Foundation,
Sask Kids Pediatrics, University of Saskatchewan**



Dr. Huntsman completed medical school and a residency in general pediatrics at Memorial University of Newfoundland. He then completed a fellowship in pediatric neurology at the University of Alberta.

For the last 12 years Dr. Huntsman has practiced pediatric neurology with the Department of Pediatrics at the University of Saskatchewan where he is an associate professor.

Dr. Huntsman's main research interest involves the use of Cannabis based therapies in children with neurological disease. He also has a clinical and research interest in pediatric epilepsy and the neurodegenerative disorders of childhood.

Dr. Huntsman is the principal investigator of the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study and is a founding member of the Cannabinoid Research Initiative of Saskatchewan (CRIS).



**Dr. Lauren E Kelly, Ph.D., M.Sc., C.C.R.P.,
Canadian Childhood Cannabinoid Clinical Trials,
Centre for Healthcare Innovation
University of Manitoba**



Dr. Lauren Kelly, PhD is a Pharmacologist and Assistant Professor in the Department of Pediatrics and Child Health at the University of Manitoba and Clinical Trialist with the George and Fay Yee Centre for Healthcare Innovation in Winnipeg, Manitoba. Dr. Kelly is the Scientific Director of the Canadian Childhood Cannabinoids Clinical Trials (C4T), a national network to study the safety and effectiveness of cannabis used for medical purposes in children. She completed a PhD in Pharmacology and Toxicology at the University of Western Ontario and two post-doctoral fellowships in Clinical Epidemiology at Mount Sinai Hospital and the Hospital for Sick Children in Toronto. She has authored more than 45 publications on child health clinical research and teaches graduate courses in clinical trials and pharmacology.



Dr. Yang Qu, Ph.D.

Assistant Professor & Cannabis Health Research Chair
University of New Brunswick



Dr. Yang Qu is an assistant professor and Cannabis Health Research Chair at University of New Brunswick. He received his PhD in biochemistry from University of Calgary, and continued his research career on manufacturing high-value plant pharmaceuticals at Brock University prior to joining UNB. His expertise in the biosynthesis of anticancer drugs will be applied to creating new bioactive cannabis pharmaceuticals, while also improving cannabis genetics suited for industrial cultivation.



Dr. Jamie R. Cox, MD



Jamie R. Cox MD, a graduate of Dalhousie Medical School, Halifax, Canada. He has spent time in multiple tiers of the health care industry in both the United States and Canada.

His prior challenges included that of a corporate leader to the Workers Compensation Board of Nova Scotia to improve healthcare and quality outcomes. This has been accomplished by developing strategic initiatives and stakeholder engagement. His broad experience in medical fields of both Canada and the United States gives him a unique ability to realize opportunities and pitfalls in both systems. A prior role was that of Corporate Medical Director of Saturn Corp., Springhill TN where his leadership responsibilities encompassed health care initiatives, disability, workers compensation, health and safety, and work related injuries and illnesses. Dr. Cox has been successful in developing strategies for containment in health care costs in industry and the general population while also improving outcomes for injuries and illnesses.

Over the last three years he has offered consultative services in the "medical cannabis" space while also evaluating over 3000 patients on referral from specialists and primary care physicians. He has successfully improved quality of life outcomes while instituting dramatic decreases in pharmaceutical utilization inclusive of narcotics.



Martha Smit

*Partner, Qualified registered nurse
and lawyer*

Fasken, Johannesburg

FASKEN



Martha Smit is a partner in our Johannesburg office and a member of the firm's Life Sciences practice group.

Qualified as both a registered nurse and lawyer, Martha brings compelling experience in the legal, medical and pharmaceutical industries.

Having practised as a litigation attorney and legal advisor in the corporate sector as well as coordinating clinical data trials for an international pharmaceutical company, she is able to bring the best of both worlds in finding innovative solutions for clients and businesses in the Life Sciences area. She also holds a current Good Clinical Practice Certificate for Clinical Research.

Martha's practical experience of having worked across a number of professional health bodies and corporates has afforded her first-hand knowledge and an in-depth understanding of the challenges, opportunities and regulatory environments of this sector.



Dr. Lucas C. McCann, MSc., BSc.
Co-founder and Chief Scientific Officer
CannDelta Inc.



Dr. Lucas C. McCann is the Co-founder and Chief Scientific Officer at CannDelta Inc., a regulatory and scientific cannabis consulting firm in Toronto where he provides scientific oversight on all projects. Lucas acquired regulatory knowledge within the Health Products branch at Health Canada's Inspectorate Labs before moving into the consulting space. Leveraging his science background, he has catapulted himself to the frontlines where technology, cannabis, and regulation interface. He specializes in medicinal organic chemistry and building science-forward cannabis companies. Lucas guides his clients through Health Canada's Cannabis Regulations and the licensing process by working to create compliant business and scientific strategies for start-ups to publicly traded licensed producers.

Lucas holds a Ph.D. in Medicinal Organic Chemistry from York University, (Toronto) an MSc. in Natural Product Synthetic Chemistry from Laval University (Quebec City), and a BSc. from the Faculty of Applied Sciences at Simon Fraser University (Burnaby). He is an Associate Member of the Ontario Medical Association and a member in good standing of the National Cannabis Working Group for the Canadian Chamber of Commerce.



Dr. Olga Chernoloz
Specialist in Neuropsychopharmacology
Omnica Biotech



With a Ph.D. in Neuroscience Olga has held a number of roles in clinical trials management, drug development, biotech and pharmaceuticals. As a trained neuropharmacologist and a registered pharmacist Dr. Chernoloz, head of Omnica Biotech, helps cannabinoid space players of all sizes to guide R&D programs, run feasibility analyses and optimize business development strategy taking into consideration scientific and regulatory underpinnings. The research program for the development of cannabinoid veterinary drugs developed by her company was since adopted and successfully run through clinical trials.

Dr. Chernoloz has developed and delivered educational modules for medical and adult cannabis space in both academic and business settings. Olga has designed and delivered a course in one of the first cannabis-centric college programs at AAPS and is leading the Science of Cannabis course at the Ryerson University.

Looking to share her knowledge and experience Olga mentors participants of cannabis startup accelerator Leaf Forward. Dr. Chernoloz provides scientific advisory to companies in cannabinoid space.

Her forthcoming book Cannabis A-Z is a complete guide to the place of cannabis in the society, culture and medicine.

Before pivoting into cannabinoid field, Olga specialized in mental health research authoring number of original research articles and a chapter in an instructional book on Neurobiology of Mood Disorders.





Dr. Lalit Chordia

Founder and CEO

Thar Process, Inc.



Over the past 30 years, Lalit Chordia, Ph.D. has pioneered research and development in Supercritical Fluid Technology. As the CEO of Thar Process, Dr. Chordia has extended his knowledge through multiple industries and is now focused on cannabis and hemp. Beyond Supercritical fluid technology, Lalit is leading the space in safe practice, pushing Thar Process to be the first cannabis extraction company to be NSF certified GMP and USDA certified Organic. From creating industrial scale CO2 Extraction equipment, Dr. Chordia is now shaping the industry in terms of CO2 Purification, focusing on pesticide and fungicide remediation as well as cannabinoid separation from pilot to industrial scale.

Born in India, Lalit received his B.S. in Chemical Engineering from the India Institute of Technology before coming to Pittsburgh and he went on to get his doctorate from Carnegie Mellon University. Through his time at Thar, Dr. Chordia has been the recipient of multiple awards focused around entrepreneurship, innovation, and international business.



Sharan Sidhu

*Chief Scientific Officer &
Director of Regulatory Affairs,*
Pacific Rim Innovations



Sharan Sidhu is the Chief Scientific Officer and Director of Regulatory Affairs at Pacific Rim Innovations, an integrated product development and brand facilitator. Key objectives are to apply world-renowned expertise in extraction, proprietary formulations, product compliance and key partnerships to the next generation of cannabis products with focus on evidence-based health claims, quality and safety. Sharan has a deep understanding of the impact of regulatory directives on product development and innovation and has been a regulatory affairs specialist and scientific advisor for several industries including the Cannabis, Natural Health Products, Foods, Cosmetics, Pet and Pest Management Products. Taking everything learnt over the last decade she has a unique prospective and point of view on emergence of industries, gaps and future directions. Sharan has managed several projects as well as developed requirements for LIMS, GLP, GACP, GMP as well as methods development, vendor qualification, ISO standards and training. Sharan sits on several advisory boards, has contributed to industry by taking on special projects, volunteers for several non for-profit organizations and focuses on bridging the gap between science and industry.

Stay Tuned Additional Speakers To Be Announced!

Conference Chair:



Speaker & Conference Chair:

Dr. Willis H. Thomas, PhD, PMP, CPT

PQE Group



Willis H. Thomas, PhD, PMP, CPT has worked for large corporations and academic institutions in the areas of human resources, learning and development, quality assurance, project management, sales and marketing, measurement and evaluation, and operations. He has 17 years of experience in the pharmaceutical industry.

Dr. Thomas is adjunct faculty at the Lake Forest Graduate School of Management, International Institute for Learning and Institute of Validation Technology.

His publications have received global recognition from associations such as the Project Management Institute (PMI) where he received the Cleland Award for "The Basics of Project Evaluation and Lessons Learned." This book was an 8-year effort that enhanced the framework for the evaluation of projects using the PMBOK® Guide.

Since 2005, he has been a featured speaker on an international basis and has received numerous awards including the Apex Publication Excellence Award for implementing useful tools for project management, evaluation and training.



Conference Chair:

Laleh Bighash, B.Sc., MBA

President, Dean of Scientific Affairs

AAPS



Ms. Bighash has a Bachelor of Pharmacy, and a Bachelor degree in Pharmacology and Toxicology from University of Toronto, Canada. She also obtained her Masters degree in Business Administration (MBA) from Schulich School of Business. She is a recipient of 2019 UC-University of Toronto alumni of influence award.

She has over 25 years of experience working for number of multinational pharmaceutical and food companies such as Genpharm Inc., Bayer Corp. and Eli Lilly & Company and number of Food and Cannabis organizations in various capacities such as Research and Development, Quality Control, Quality Assurance, Regulatory and Compliance, Financial Planning, and Business development. In her current role as the President of AAPS, she oversees the consulting, educational and training direction of AAPS.

Ms. Bighash has lectured extensively and has been an invited speaker at many academic and industry events focusing on pharma and cannabis related topics such as regulatory, compliance and efficient operations. She has worked closely with the pharma and cannabis Industry players and stakeholders in formulating efficient operating systems, ensuring regulatory compliance and GMP certification.

Stay Tuned Additional Speakers To Be Announced!

Program Contents at a Glance

Day 2 & 3 - May 7-8, 2020 | Medicinal Cannabis Science & Research

Update on cannabis regulation requirements for analytical testing and research

Presented by: Céline Beaupré, *Manager of Specialized Authorization, Controlled Substances and Cannabis Branch, Health Canada*

The framework for Research and Clinical Trials: The South African context

The current status of clinical data trials for an international Medical Cannabis

Presented by: Martha Smit, *Partner, Qualified registered nurse and lawyer, Fasken, Johannesburg*

Updates on Cannabis for the treatment of pediatric epilepsy

Updated review of the CARE-E study

Presented by: Dr. Richard J. Huntsman, *MD, FRCP(C), CSCN(EEG), Jim Pattison Children's Hospital, Foundation, University of Saskatchewan*

"Medical" cannabis and chronic disease management in the aging population

- Cannabis use is growing in the senior population – is the Canadian healthcare system keeping pace ?
- Cannabis use vs pharmaceutical use : patient experiences and risks
- Challenges with cannabis research : practical and theoretical

Presented by: Dr. Jamie R. Cox, *MD*

Cannabis used for medical purposes in children

A growing number of pediatricians in Canada report that children and young adults are using cannabis for a variety of medical purposes including cancer symptoms, pain, sleep and neurological conditions among others. This talk will cover

- Perspectives on cannabis use for child health concerns
- The need for clinical trials
- Steps forward to evidence-based medical cannabis use in children

Presented by: Lauren E Kelly Ph.D., *M.Sc., C.C.R.P., University of Manitoba, Canadian Childhood Cannabinoid Clinical Trials, Centre for Healthcare Innovation*

Phytochemistry of cannabis and the development of bioactive compounds from cannabis

- Phytochemistry of cannabis
- Trends in developing cannabis plant genetics
- Trends in the biosynthesis of cannabinoids
- Trends in the biosynthesis of non-cannabinoid phytochemicals

Presented by: Dr. Yang Qu, *assistant professor and Cannabis Health Research Chair at University of New Brunswick*

Minor cannabinoids – major deal

With the restrictions on cannabinoid research finally easing off we are learning more and more about the therapeutic properties of cannabis beyond THC and CBD. New data shines the light at the vast potential minor cannabinoids may carry.

- Existing data on efficacy of minor cannabinoids
- Pharma and biotech interest in minor cannabinoid drug development
- Cannabinoid biosynthesis feasible for production of minor cannabinoids
- Discovery and characterization of novel cannabinoid molecules

Presented by: Dr. Olga Chernoloz, *Specialist in Neuropsychopharmacology, Head of Omnica Biotech*

Program Contents at a Glance

Day 2 & 3 - May 7-8, 2020 | Medicinal Cannabis Science & Research

Cannabis and Novel Drug Delivery Methods

Presented by: Dr. Lucas C. McCann, MSc., BSc., Co-founder and Chief Scientific Officer, CannDelta Inc.

Opportunities and challenges of developing safe cannabis products and efficacious cannabis therapeutics

"Although the Cannabis Industry is in its infancy Cannabis it has been described as one of "humanities older crops". It has many ancient uses and referenced in several historical texts including Materia Medica from China and India as well as ancient Egyptian Papyrus. Historically it has been used therapeutically for centuries and is still being used for many ailments, without any evidence bar anecdotal or traditional use.

The Canadian market has seen cannabis prescription drugs, smokable bud and vapes and more recently edibles and topicals all of which have not provided consumers with an alternative to black market products that have been used for therapeutic purposes. Cannabis Health Products frameworks, however, does provide an opportunity for safe, effective and quality products to come to the market.

Development pipelines not only need to consider the same challenges that other cannabis product categories have reported, for example contamination, formulation and ingredient stability and homogeneity, but will also studies related to safety and efficacy".

Particularly this presentation will focus on ingredient and formulation complexities in the development of cannabis shelf stable products.

Presented by: Sharan Sidhu, Chief Scientific Officer & Director of Regulatory Affairs, Pacific Rim Innovations

Risk Evaluation Management Strategies (REMS) for Cannabis Therapies

REMS is a drug safety program the United States Food and Drug Administration (FDA) can require for certain medications, which have been determined to have safety concerns to ensure the benefits of the therapy outweigh its risks.

Traditional views regarding REMS programs primarily concerned highly addictive drugs, such as opiates. However, with the increasing number of cannabis therapies, i.e., medical marijuana prescriptions for therapeutic applications, there is a need to consider dependence on cannabis in all of its forms for medicinal use.

This presentation discusses:

- Emerging REMS-type programs for cannabis therapies
- Development of a shared system for REMS for cannabis therapies
- The decisions that need to be made in order to promote positive REMS enforcement to patients

Presented by: Dr. Willis H. Thomas, PhD, PMP, CPT, PQE Group

Using SFC (CO2 Purification) to create cannabinoid isolates or remediate undesirable compounds from hemp extract.

As the cannabis industry continues to change, what is considered to be a desired product will change as well, creating a need for the ability to produce said products. This talk will cover:

- Isolating one or multiple cannabinoids from full spectrum extract
- The remediation of harmful compounds such as pesticides and fungicides from extracts
- The ability to grow from pilot to industrial scale without any significant losses

Presented by: Dr. Lalit Chordia, Founder and CEO, Thar Process, Inc. and Thar Energy LLC

Note: Agenda is subject to change without notice. Please check back regularly for updates.

Stay Tuned Additional Topics and Detail agenda To Be Announced!

Exhibition Opportunities



Interested in Exhibiting at this event?
Contact us at 416-410-7402
or enquiry@ipacanada.com

IPA Speaking Opportunities

Interested in presenting at one of our upcoming events?

We are continually looking for industry experts to present at our international conferences throughout the world and to share their in-depth knowledge of their speciality with our attendees. If you have an interest in becoming one of our select cadre of experts, please contact us at:

Tel: 416-410-7402 or enquiry@ipacanada.com



Venue and Hotel Accommodation:



Holiday Inn Toronto International Airport

970 Dixon Road, Rexdale, Toronto, Ontario, M9W1J9 | Tel: 1 416-675-7611

The Holiday Inn Toronto International Airport (YYZ) is a newly renovated airport hotel conveniently located minutes from Toronto's Pearson International Airport. Easy access to highway 401, 427 and 407. .

Guests are responsible for their own accommodations.

IPA is arranging a special room rate for attendees at the Holiday Inn Toronto Airport (Venue). **Stay Tuned for a special group rate and group code!.**

For more information, please call us
at 416-410-7402 or
enquiry@ipacanada.com



REGISTRATION FORM

IPA 2020 Medicinal Cannabis Conference on:

Import & Export of Medicinal Cannabis | May 6, 2020

Medicinal Cannabis Science & Research | May 7-8, 2020

	EARLY BIRD: Before March 13, 2020	REGULAR RATE: March 14, 2020 – May 5, 2020	ONSITE: May 6-8, 2020
1 DAY EVENT ONLY	\$425 CAD + HST (SAVE \$100)	\$525 CAD + HST	\$625 CAD + HST
2 DAY EVENT	\$748 CAD + HST (SAVE OVER \$200)	\$848 CAD + HST (SAVE MORE ON 2 DAY REGISTRATION)	\$948 CAD + HST
3 DAY EVENT	\$975 CAD + HST (SAVE OVER \$300)	\$1085 CAD + HST (SAVE MORE ON 3 DAY REGISTRATION)	\$1185 CAD + HST

Group Discount: Special group rates available for 3 or more registrants. Some restriction applies., please contact us by email: enquiry@ipacanada.com or Call: 416-410-7402

ACADEMIA / GOVERNMENT RATES:	1 DAY EVENT ONLY	2 DAY EVENT	3 DAY EVENT
	\$315 + HST CAD	\$535 + HST CAD	\$835 + HST CAD

Name: _____ Job title: _____

Company: _____ Address: _____

City: _____ State/Province: _____ Zip/Postal code: _____

Telephone: _____ Fax: _____ E-Mail: _____

Signature: _____ Group Registration Info: _____

Promo Code: _____

For registration or any further information, please contact us at:

Mail: International Pharmaceutical Academy 420 Highway 7 East, Box 82022, Richmond Hill, Ontario, Canada L4B 3K0	Call: 416 410 7402	Website: https://ipacanada.com
	Fax: 1 888-236-5480	Email: enquiry@ipacanada.com

PAYMENT METHODS (Please check payment method):

☐ CHEQUE/S

Please make your cheque/s payable to:
"INTERNATIONAL PHARMACEUTICAL ACADEMY INC."

☐ COMPANY P.O.

Please provide company's P.O. Number:

CREDIT CARD

☐ VISA 

☐ MC 

☐ AMEX 

Card Number: _____

Exp. Date: _____ CVV/CVC: _____

Name (as shown on card): _____

Billing Address: _____

Signature (required): _____

Authorization No. (for office use only)

Date:

Cancellation/Substitutions Policy:

All cancellations are subject to a CAD \$150.00/person processing fee. To receive cancellation credits for attendance at an upcoming course, IPA must be notified of the cancellation in writing (by email, mail or fax) up to 3 weeks prior to the program start date. Cancellations submitted less than 3 weeks prior to the event will not be qualified for refund or credit.

Substitution of delegate/s with the member/s of the same organization is permitted at any time with no penalty.

IPA reserves the right to postpone an event, prior to which time all the registered attendees will be notified a minimum of 2 weeks in advance. IPA shall not be responsible for any air fare, hotel or transportation costs incurred by registrant/s.